Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer

NCT05816252 is registered in ClinicalTrials.gov with Klus Pharma Inc. as lead sponsor.

NCT NCT05816252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05816252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Klus Pharma Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 19, 2023
Completion date
December 30, 2026
Enrollment
356 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer